DigiSight Technologies has raised $7.8 million in a Series B financing from both new and existing investors. New investors included Biosys Capital, Waycross Ventures, GE Ventures and Lagunita LLC.

The company’s core technology, called the DigiSight Network, creates a secure connection for data from mobile devices to move seamlessly into clinical settings.

The company’s core technology, called the DigiSight Network, creates a secure connection for data from mobile devices to move seamlessly into clinical settings.The first specialty in DigiSight’s commercialization strategy is ophthalmology; patients generate ophthalmic data using mobile devices and share that data with permissioned care providers in real-time. These tests provide physicians insight into patient performance between regular office examinations, unlocking the true potential of remote patient monitoring and data analytics.

The company will use the proceeds from the financing to continue developing the DigiSight Network and other specialized remote monitoring technologies with an expanded team.

DigiSight was founded by Drs. Mark Blumenkranz and Daniel Palanker of Stanford University, who believe that mobile technologies can help deliver care more efficiently. Dr. Blumenkranz is the H.J. Smead Professor and Chairman of the Department of Ophthalmology at Stanford University. On the other hand, Dr. Palanker is a Professor of Ophthalmology at the Hansen Experimental Physics Laboratory at Stanford University. He is an expert in light and laser-based systems in ophthalmology.